{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T23:30:01Z","timestamp":1768260601571,"version":"3.49.0"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2016,10,11]],"date-time":"2016-10-11T00:00:00Z","timestamp":1476144000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100000272","name":"National Institute for Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Ophthalmol"],"published-print":{"date-parts":[[2017,10]]},"DOI":"10.1007\/s10792-016-0370-9","type":"journal-article","created":{"date-parts":[[2016,10,11]],"date-time":"2016-10-11T01:17:49Z","timestamp":1476148669000},"page":"1229-1233","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Alemtuzumab-induced remission of multiple sclerosis-associated uveitis"],"prefix":"10.1007","volume":"37","author":[{"given":"Mark D.","family":"Willis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Trevor P.","family":"Pickersgill","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neil P.","family":"Robertson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard W. J.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew D.","family":"Dick","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0055-9547","authenticated-orcid":false,"given":"Ester","family":"Carre\u00f1o","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,10,11]]},"reference":[{"issue":"9856","key":"370_CR1","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1016\/s0140-6736(12)61769-3","volume":"380","author":"JA Cohen","year":"2012","unstructured":"Cohen JA, Coles AJ, Arnold DL, Confavreux C, Fox EJ, Hartung H-P, Havrdova E, Selmaj KW, Weiner HL, Fisher E, Brinar VV, Giovannoni G, Stojanovic M, Ertik BI, Lake SL, Margolin DH, Panzara MA, Compston DAS (2012) Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet 380(9856):1819\u20131828. doi:\n                        10.1016\/s0140-6736(12)61769-3","journal-title":"Lancet"},{"issue":"4","key":"370_CR2","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1016\/s1474-4422(11)70020-5","volume":"10","author":"AJ Coles","year":"2011","unstructured":"Coles AJ, Fox E, Vladic A, Gazda SK, Brinar V, Selmaj KW, Bass AD-D, Wynn DR, Margolin DH, Lake SL, Moran S, Palmer J, Smith MS, Compston DAS (2011) Alemtuzumab versus interferon beta-1a in early relapsing-remitting multiple sclerosis: post hoc and subset analyses of clinical efficacy outcomes. Lancet Neurol 10(4):338\u2013348. doi:\n                        10.1016\/s1474-4422(11)70020-5","journal-title":"Lancet Neurol"},{"issue":"17","key":"370_CR3","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1056\/NEJMoa0802670","volume":"359","author":"AJC Coles","year":"2008","unstructured":"Coles AJC, Compston DA, Selmaj KW et al (2008) Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. N Engl J Med 359(17):1786\u20131801","journal-title":"N Engl J Med"},{"issue":"3","key":"370_CR4","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1080\/146532401753174098","volume":"3","author":"G Hale","year":"2001","unstructured":"Hale G (2001) The CD52 antigen and development of the CAMPATH antibodies. Cytotherapy 3(3):137\u2013143. doi:\n                        10.1080\/146532401753174098","journal-title":"Cytotherapy"},{"issue":"6","key":"370_CR5","doi-asserted-by":"publisher","first-page":"e39416","DOI":"10.1371\/journal.pone.0039416","volume":"7","author":"SP Rao","year":"2012","unstructured":"Rao SP, Sancho J, Campos-Rivera J, Boutin PM, Severy PB, Weeden T, Shankara S, Roberts BL, Kaplan JM (2012) Human peripheral blood mononuclear cells exhibit heterogeneous CD52 expression levels and show differential sensitivity to alemtuzumab mediated cytolysis. PLoS One 7(6):e39416. doi:\n                        10.1371\/journal.pone.0039416","journal-title":"PLoS One"},{"issue":"1","key":"370_CR6","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.clim.2011.04.006","volume":"142","author":"L Klotz","year":"2012","unstructured":"Klotz L, Meuth SG, Wiendl H (2012) Immune mechanisms of new therapeutic strategies in multiple sclerosis-A focus on alemtuzumab. Clin Immunol 142(1):25\u201330. doi:\n                        10.1016\/j.clim.2011.04.006","journal-title":"Clin Immunol"},{"issue":"10","key":"370_CR7","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1136\/bjo.2004.061119","volume":"89","author":"MD Becker","year":"2005","unstructured":"Becker MD, Heiligenhaus A, Hudde T, Storch-Hagenlocher B, Wildemann B, Barisani-Asenbauer T, Thimm C, Stubiger N, Trieschmann M, Fiehn C (2005) Interferon as a treatment for uveitis associated with multiple sclerosis. Br J Ophthalmol 89(10):1254\u20131257. doi:\n                        10.1136\/bjo.2004.061119","journal-title":"Br J Ophthalmol"},{"issue":"2","key":"370_CR8","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1136\/bjophthalmol-2014-305518","volume":"99","author":"W Messenger","year":"2015","unstructured":"Messenger W, Hildebrandt L, Mackensen F, Suhler E, Becker M, Rosenbaum JT (2015) Characterisation of uveitis in association with multiple sclerosis. Br J Ophthalmol 99(2):205\u2013209. doi:\n                        10.1136\/bjophthalmol-2014-305518","journal-title":"Br J Ophthalmol"},{"key":"370_CR9","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1136\/bjo.84.1.107","volume":"84","author":"AD Dick","year":"2000","unstructured":"Dick AD, Meyer P, James T, Forrester JV, Hale G, Waldmann H, Isaacs JD (2000) Campath-1H therapy in refractory ocular inflammatory disease. Br J Ophthalmol 84:107\u2013109","journal-title":"Br J Ophthalmol"},{"issue":"11","key":"370_CR10","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1136\/bjo.79.11.1054","volume":"79","author":"JD Isaacs","year":"1995","unstructured":"Isaacs JD, Hale G, Waldmann H, Dick AD, Haynes R, Forrester JV, Watson P, Meyer PA (1995) Monoclonal antibody therapy of chronic intraocular inflammation using Campath-1H. Br J Ophthalmol 79(11):1054\u20131055","journal-title":"Br J Ophthalmol"},{"issue":"12","key":"370_CR11","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1093\/rheumatology\/keg424","volume":"42","author":"CM Lockwood","year":"2003","unstructured":"Lockwood CM, Hale G, Waldman H, Jayne DR (2003) Remission induction in Behcet\u2019s disease following lymphocyte depletion by the anti-CD52 antibody CAMPATH 1-H. Rheumatology 42(12):1539\u20131544. doi:\n                        10.1093\/rheumatology\/keg424","journal-title":"Rheumatology"},{"issue":"3","key":"370_CR12","doi-asserted-by":"publisher","first-page":"1872","DOI":"10.1167\/iovs.10-6909","volume":"52","author":"RR Caspi","year":"2011","unstructured":"Caspi RR (2011) Understanding autoimmune uveitis through animal models. The Friedenwald Lecture. Invest Ophthalmol Vis Sci 52(3):1872\u20131879. doi:\n                        10.1167\/iovs.10-6909","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"3","key":"370_CR13","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1136\/jnnp-2011-300826","volume":"83","author":"GA Hill-Cawthorne","year":"2012","unstructured":"Hill-Cawthorne GA, Button T, Tuohy O, Jones JL, May K, Somerfield J, Green A, Giovannoni G, Compston DA, Fahey MT, Coles AJ (2012) Long term lymphocyte reconstitution after alemtuzumab treatment of multiple sclerosis. J Neurol Neurosurg Psychiatry 83(3):298\u2013304. doi:\n                        10.1136\/jnnp-2011-300826","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"24","key":"370_CR14","doi-asserted-by":"crossref","first-page":"2158","DOI":"10.1212\/WNL.0000000000000520","volume":"82","author":"OAL Kousin-Ezewu","year":"2014","unstructured":"Kousin-Ezewu OAL, Parker RA et al (2014) Accelerated lymphocyte recovery after alemtuzumab does not predict multiple sclerosis activity. Neurology 82(24):2158\u20132164","journal-title":"Neurology"},{"issue":"1","key":"370_CR15","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/s10875-009-9327-3","volume":"30","author":"SA Thompson","year":"2010","unstructured":"Thompson SA, Jones JL, Cox AL, Compston DA, Coles AJ (2010) B-cell reconstitution and BAFF after alemtuzumab (Campath-1H) treatment of multiple sclerosis. J Clin Immunol 30(1):99\u2013105. doi:\n                        10.1007\/s10875-009-9327-3","journal-title":"J Clin Immunol"},{"issue":"12","key":"370_CR16","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1586\/ern.10.135","volume":"10","author":"F Ej","year":"2010","unstructured":"Ej F (2010) Alemtuzumab in the treatment of relapsing-remitting multiple sclerosis. Expert Rev Neurother 10(12):1789\u20131797","journal-title":"Expert Rev Neurother"},{"issue":"2","key":"370_CR17","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1111\/j.1365-2567.2009.03115.x","volume":"128","author":"Y Hu","year":"2009","unstructured":"Hu Y, Turner MJ, Shields J, Gale MS, Hutto E, Roberts BL, Siders WM, Kaplan JM (2009) Investigation of the mechanism of action of alemtuzumab in a human CD52 transgenic mouse model. Immunology 128(2):260\u2013270. doi:\n                        10.1111\/j.1365-2567.2009.03115.x","journal-title":"Immunology"},{"issue":"10","key":"370_CR18","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1007\/s00277-004-0917-0","volume":"83","author":"M Stanglmaier","year":"2004","unstructured":"Stanglmaier M, Reis S, Hallek M (2004) Rituximab and alemtuzumab induce a nonclassic, caspase-independent apoptotic pathway in B-lymphoid cell lines and in chronic lymphocytic leukemia cells. Ann Hematol 83(10):634\u2013645. doi:\n                        10.1007\/s00277-004-0917-0","journal-title":"Ann Hematol"},{"issue":"9","key":"370_CR19","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1177\/1352458515614092","volume":"22","author":"MD Willis","year":"2015","unstructured":"Willis MD, Harding KE, Pickersgil T et al (2015) Alemtuzumab for multiple sclerosis: Long term follow-up in a multi-centre cohort. Mult Sclerosis 22(9):1215\u20131223","journal-title":"Mult Sclerosis"}],"container-title":["International Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10792-016-0370-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10792-016-0370-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10792-016-0370-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,10,9]],"date-time":"2017-10-09T01:17:55Z","timestamp":1507511875000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10792-016-0370-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10,11]]},"references-count":19,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2017,10]]}},"alternative-id":["370"],"URL":"https:\/\/doi.org\/10.1007\/s10792-016-0370-9","relation":{},"ISSN":["0165-5701","1573-2630"],"issn-type":[{"value":"0165-5701","type":"print"},{"value":"1573-2630","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,10,11]]}}}